期刊
FRONTIERS IN GENETICS
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2021.620859
关键词
methyl CpG binding protein 2; Rett syndrome; mutations; protein stability; RNA binding
资金
- Ontario Rett Syndrome Association (ORSA)
- Canadian Institutes of Health Research
- (CIHR) [MOP-130417]
- Natural Sciences and Engineering Research Council of Canada (NSERC) CGS-M fellowship
Mutations in MeCP2 gene are the main cause of Rett syndrome, a neurodevelopmental disorder characterized by a period of normal development followed by regression. MeCP2 protein has multiple functions, including binding to methylated genomic DNA and playing a significant role in neuronal development. The variability in MeCP2 stability and its relationships with mRNA splicing, miRNA processing, and other non-coding RNAs may contribute to the epigenetic consequences of MeCP2 genetic ablation.
Mutations in methyl CpG binding protein 2 (MeCP2) are the major cause of Rett syndrome (RTT), a rare neurodevelopmental disorder with a notable period of developmental regression following apparently normal initial development. Such MeCP2 alterations often result in changes to DNA binding and chromatin clustering ability, and in the stability of this protein. Among other functions, MeCP2 binds to methylated genomic DNA, which represents an important epigenetic mark with broad physiological implications, including neuronal development. In this review, we will summarize the genetic foundations behind RTT, and the variable degrees of protein stability exhibited by MeCP2 and its mutated versions. Also, past and emerging relationships that MeCP2 has with mRNA splicing, miRNA processing, and other non-coding RNAs (ncRNA) will be explored, and we suggest that these molecules could be missing links in understanding the epigenetic consequences incurred from genetic ablation of this important chromatin modifier. Importantly, although MeCP2 is highly expressed in the brain, where it has been most extensively studied, the role of this protein and its alterations in other tissues cannot be ignored and will also be discussed. Finally, the additional complexity to RTT pathology introduced by structural and functional implications of the two MeCP2 isoforms (MeCP2-E1 and MeCP2-E2) will be described. Epigenetic therapeutics are gaining clinical popularity, yet treatment for Rett syndrome is more complicated than would be anticipated for a purely epigenetic disorder, which should be taken into account in future clinical contexts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据